Articles tagged with Clinical Trials
A groundbreaking study published in JAMA found that excluding aspirin from the antithrombotic regimen for patients with a fully magnetically levitated left ventricular assist device (LVAD) resulted in a significant decrease in major nonsurgical bleeding events. This approach is safe and beneficial, challenging conventional practice and...
A systematic review of 13 randomized clinical trials found that app-based interventions are effective in treating moderate to severe depression. The study's findings support the use of mobile apps as a practical tool for clinical practice.
A randomized clinical trial of 1,175 participants found that treatment with higher-dose fluvoxamine did not improve time to sustained recovery in outpatients with mild to moderate COVID-19. The study compared fluvoxamine 100 mg twice daily for 13 days to placebo.
Research of 155,000 births finds birth at 39 weeks' gestation is linked to better educational outcomes compared to earlier or later births. No significant differences in numeracy and literacy skills were found between children born at 39 versus 40-42 weeks
Two phase-3 clinical trials demonstrate a significant increase in overall survival and progression-free survival for bladder cancer patients treated with immunotherapy combinations. The studies show a 22% reduction in the risk of death compared to chemotherapy alone, providing a promising new approach for treating advanced bladder cancer.
Researchers found a modest improvement in predicting pathologic response to chemotherapy using molecular subtypes, but no association with overall survival and progression-free survival. The study suggests the need for subtype-directed therapy trials to test targeted treatments.
Researchers have made a breakthrough in understanding the genetic changes that occur during tumor migration, and discovered a drug that can obstruct this process. A new clinical trial at the University of Rochester's Wilmot Cancer Institute will test the effectiveness of the experimental drug NP137.
The University of Basel has successfully treated over 100 patients with focal lesions and two advanced cases of knee OA, reporting beneficial outcomes. The N-TEC procedure uses autologous cartilage cells to grow new cartilage grafts for repairing damaged joints, offering an alternative to knee joint replacements.
Researchers aim to optimize digital weight-loss programs for rural populations by adding human components, such as weekly group video sessions and individual coaching calls. The goal is to help residents manage their weight and fight the obesity epidemic in areas with limited access to in-person programs.
A new resorbable scaffold has been shown to be more effective than traditional angioplasty in treating severe artery blockages in the lower leg. In a large clinical trial, patients who received the scaffold had a 74% chance of avoiding adverse events, compared to 44% for those who underwent angioplasty.
A randomized clinical trial of 2,858 patients with new-onset and worsening chronic heart failure shows that torsemide and furosemide have no significant difference in clinical or patient-reported outcomes at 12 months. Torsemide is associated with better outcomes for patients with de novo heart failure.
Researchers found that abelacimab, a Factor XI inhibitor, reduced bleeding compared to rivaroxaban in patients with atrial fibrillation. The study showed significant reduction in hospitalization due to bleeding and almost eliminated gastrointestinal bleeding.
A phase 1 trial shows that a single dose of lepodisiran can reduce blood levels of lipoprotein(a) by up to 96%, a key driver of heart disease risk. The therapy, which blocks the production of lipoprotein(a), is well-tolerated and has long-lasting effects.
Patients with heart failure treated with dapagliflozin experienced frequent initial estimated glomerular filtration rate declines, but without increased cardiovascular or kidney event risks. The study suggests that sodium-glucose cotransporter-2 inhibitors can be safely continued in patients experiencing eGFR decline.
A randomized clinical trial found that self-monitoring and physician-guided titration of antihypertensive medications reduced postpartum blood pressure compared to usual care. The study involved 220 participants in the UK and showed promising results for long-term blood pressure control.
A natural language processing model was validated to identify heart failure hospitalizations in a multicenter clinical trial, demonstrating its potential to improve the efficiency of future trials. The study suggests that natural language processing can be used at scale to identify clinical events, but further research is needed.
A randomized clinical trial found that avoiding aspirin as part of an antithrombotic regimen reduces bleeding events without increasing thromboembolism risk in patients with advanced heart failure treated with left ventricular assist devices. The study suggests that aspirin avoidance may be a viable option for these patients.
Treatment with obinutuzumab has been shown to preserve kidney function and prevent flares in patients with lupus nephritis. The addition of obinutuzumab to standard treatment reduced the risk of composite outcomes, such as death or treatment failure, by 60%.
A clinical trial found that high levels of anti-Ro/SSA antibodies in pregnant women are associated with an increased risk of fetal atrioventricular block (AVB), a condition that can be fatal. Home-based fetal heart rate monitoring reliably detects conduction abnormalities, potentially reducing the need for serial echocardiograms.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
A recent study published in eClinical Medicine found that the GB510/AS03 vaccine elicited a stronger antibody immune response against the ancestral SARS-CoV-2 strain compared to ChAdOx1-S. The vaccine demonstrated robust safety and efficacy, with no significant safety concerns identified.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
Researchers found that changing treatment can lead to significant improvement in mobility and quality of life for patients with advanced Parkinson's disease. A nationwide registry is planned to develop scientifically sound guidelines for combination therapies.
Researchers discovered that patients with FSGS who received sparsentan treatment experienced improved kidney function and reduced proteinuria, a key indicator of kidney damage. The study suggests sparsentan may be a potential new treatment option for the disorder, offering hope for patients affected by FSGS.
A novel multicomponent intervention aimed at improving patient access to kidney transplants did not significantly increase the rate of completed steps in a randomized clinical trial involving 20,375 patients. The study highlights the need for sustained efforts to address barriers to transplantation globally.
Researchers found that urine biomarkers can be more accurate than serum biomarkers for detecting specific diseases. The study highlights the potential of combining urinary and serum biomarkers for holistic disease diagnosis and management. However, challenges remain in standardizing urinary biomarker assays and expanding their applicat...
A new study from Tulane University found that frequent salt consumption is associated with a higher risk of developing Type 2 diabetes. The study surveyed over 400,000 adults and found participants who regularly added salt had a 13% to 39% increased risk of developing the disease compared to those who never or rarely used salt.
A new study by RCSI University of Medicine and Health Sciences found that boosting levels of a deficient protein improves survival rates for people with severe alpha-1 antitrypsin deficiency. The research, which tracked health data from over 600 patients, showed a clear survival benefit from augmentation therapy.
A new phase 3 clinical trial found that once-weekly basal injection of icodec to treat type 1 diabetes showed non-inferiority to daily insulin degludec in reducing HbA1C levels. However, higher rates of hypoglycaemic episodes were noted in the icodec group.
The University of Cincinnati will continue to oversee U.S. NIH-funded stroke trials for the next five years, with Pooja Khatri, MD, MSc, leading as Lead PI. The renewed infrastructure includes new features such as patient representation and advocacy initiatives, aiming to advance stroke care worldwide.
University of Alberta researchers have identified taurine as a key player in predicting poor clinical outcomes and treating long COVID. A predictive test and proposed supplement trial aim to minimize symptoms and improve patient outcomes.
A randomized clinical trial of 524 trauma patients found that adding sigh breaths to mechanical ventilation did not increase ventilator-free days. However, prespecified secondary data suggest that sighs are well-tolerated and may improve clinical outcomes in this patient population.
A randomized clinical trial involving 126 patients found that landiolol did not prevent organ failure in those with established septic shock. The study concluded that this beta-blocker is not a suitable treatment option for managing tachycardia in these patients.
A brain-computer interface (BCI) has been successfully used to restore control of home devices for a patient with ALS, allowing the individual to navigate a communication board and smart devices without recalibration. The BCI device was implanted on the surface of the brain areas responsible for speech and upper limb function, enabling...
Researchers found no significant improvement in primary composite outcomes, including organ support-free days and hospital survival, among hospitalized patients with COVID-19 who received intravenous vitamin C. The study suggests that vitamin C treatment may not be effective in improving patient outcomes for this population.
A global platform study has released results on the use of simvastatin to treat severely ill patients with COVID-19, showing a high probability of improving outcomes. In contrast, high-dose vitamin C was found to be ineffective and potentially harmful in critically ill patients, suggesting its use should be discontinued.
Tongxinluo significantly improved 30-day and 1-year clinical outcomes in STEMI patients, according to a randomized clinical trial. Further research is needed to understand its mechanism of action.
A new multitarget stool RNA test, ColoSense, has been shown to detect colorectal neoplasia with high sensitivity and comparable specificity to existing molecular diagnostic tests. The test also demonstrated significant improvement in sensitivity relative to the fecal immunochemical test.
Researchers saw a major pathologic response in over half of surgical specimens from patients treated with neoadjuvant pembrolizumab. The treatment shrank over half of advanced melanomas, according to exploratory analyses presented at the European Society of Medical Oncology (ESMO) Congress 2023.
Researchers at Penn Medicine have received a $10 million grant to develop a new strategy for preventing breast cancer recurrence by targeting dormant tumor cells. In a phase II clinical trial, the team successfully cleared dormant cells from over 80% of patients, offering a promising proof-of-concept for this approach.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A Phase III trial found that combining durvalumab and olaparib with chemotherapy reduces disease progression in advanced endometrial cancer patients by 45%, compared to 29% with durvalumab alone. The combination also shows benefits in MMR-proficient subgroups, offering new treatment options for these patients.
A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...
A randomized clinical trial found that high-frequency electrical stimulation device reduced opioid use and prescribed opioids after cesarean delivery, suggesting a potential adjunct to decrease opioid use without compromising pain control.
A new hormone replacement therapy, Pulsatility, has shown promising results in improving symptoms and quality of life for patients with adrenal insufficiency conditions. The treatment, which delivers hydrocortisone in a pulsatile pattern, decreased fatigue by 10% and improved mood and energy levels by 30%.
A retrospective study found that research staff of the same race or ethnicity as patients increased consent rates by 65.1% compared to those of a different race or ethnicity. Employing diverse research teams can improve trust and engagement among potential study participants, according to researchers.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
A study published in Psychological Medicine found that the widely prescribed sedative alprazolam XR may be less effective than believed, with publication bias inflating its efficacy by over 40%. This suggests caution for patients and clinicians starting a prescription for panic disorder.
In a phase I trial, an oncolytic virus treatment designed by Brigham researchers extended survival among patients with recurrent glioblastoma, especially those with pre-existing viral antibodies. The therapy reshaped the tumor's surrounding environment to stimulate an anti-tumor immune response.
A randomized clinical trial found that cefepime increased neurological dysfunction in adults hospitalized with acute infection, while piperacillin-tazobactam did not. The study involved 2,511 participants and suggested that cefepime may be associated with adverse outcomes.
A new technique to control severe bleeding in injured patients has been found to increase the risk of death. The REBOA treatment was tested in a clinical trial involving 90 adult trauma patients, but it did not show the expected benefits.
A Monash University study found that methotrexate, a low-cost and effective treatment for inflammatory joint conditions, can reduce pain and stiffness in patients with symptomatic hand OA. The study's results suggest that methotrexate may be a viable treatment option for people with hand osteoarthritis and inflammation.
Researchers conducted a randomized trial in Canadian ICUs, finding that switching to small-volume blood collection tubes lowered red blood cell transfusion rates. The study suggests this change may improve patient outcomes and reduce the need for transfusions.
The new guidelines recommend a more restrictive approach to determine optimal treatment for patients who may not need red blood cell transfusions. The panel took into account the clinical context, co-morbidities, symptoms, and signs of each patient to ensure personalized care.
A world-first clinical trial published in JAMA found that using small-volume tubes reduced the need for almost one blood transfusion for every 10 patients. The study saved about 1,500 units of blood and may provide an easy way to save tens of thousands of units worldwide.
A clinical trial led by Western Sydney University's NICM Health Research Institute has revealed that Sailuotong, a novel herbal extract, shows promise as a potential treatment for mild cognitive impairment. The study found improvements in memory and executive function in participants taking SLT compared to those on a placebo.
A new clinical trial has shown that infusing immune cells from living donors into recipients before transplantation may reduce the need for lifelong immunosuppressant medication. The treatment involves infusing donor-derived regulatory dendritic cells, which help the recipient's immune system distinguish between foreign and self-cells.
A large multi-state study found that mupirocin ointment is highly effective at preventing Staphylococcus aureus infections in critically ill patients, outperforming an antiseptic solution. The study involved over 800,000 ICU patients in 137 hospitals and showed a durable benefit from mupirocin.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.